What is the 13F Pro Quality Score for LFCR?

13F Pro ranks LIFECORE BIOMEDICAL, INC. \DE\ (LFCR) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View LFCR's current score at https://13fpro.ai/research/LFCR (free sign-up required for the full ranking).

Which hedge funds own the most LFCR stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of LFCR include 22NW,, WYNNEFIELD CAPITAL, Legion Partners Asset Management,. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/LFCR as soon as new 13F filings post.

Where does 13F Pro source LFCR data?

All LIFECORE BIOMEDICAL, INC. \DE\ fundamentals and ownership data come directly from SEC EDGAR. LIFECORE BIOMEDICAL, INC. \DE\ files with the SEC under CIK 1005286. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is LFCR in?

LIFECORE BIOMEDICAL, INC. \DE\ (LFCR) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is LFCR research updated on 13F Pro?

LFCR's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

LIFECORE BIOMEDICAL, INC. \DE\(LFCR)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1005286 LFCR stock profile & AI dashboard →

13F Pro Quality Score

15.3/100

Rank #2,749 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

2.5/100

Profitability

11.2/100

Balance Sheet

10.5/100

Earnings Quality

30.0/100

Free Cash Flow

17.9/100

Institutional Flow

58.3/100

Revenue Scale

19.0/100

Dilution Risk

20.5/100

LFCR Stock Analysis & AI Quality Score

AI stock analysis and institutional research for LIFECORE BIOMEDICAL, INC. \DE\ (LFCR), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores LFCR at 15.3/100 on a 32-signal composite quality model, placing it at rank #2,749 of 2,879 stocks — the bottom half of the AI-ranked universe. Areas of concern include revenue growth (2.5) and balance sheet strength (10.5), which score below median versus the broader universe. Shareholder dilution risk is elevated at 20.5/100, reflecting ongoing share issuance or stock-based compensation. Top institutional holders of LFCR by reported 13-F value include 22NW,, WYNNEFIELD CAPITAL, Legion Partners Asset Management,, based on the most recent SEC filings. LFCR trades on the Nasdaq exchange and files with the SEC under CIK 1005286. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate LFCR daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for LIFECORE BIOMEDICAL, INC. \DE\ directly from SEC EDGAR. LIFECORE BIOMEDICAL, INC. \DE\'s 13F Pro composite quality score has ranged between 15 and 40 since 2024, currently 15.3 — a declining long-term trajectory across 13 quarterly and live scoring snapshots.

✦

Fun facts about LIFECORE BIOMEDICAL, INC. \DE\

Quirks, history, and lore behind LFCR — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. healthcare company · small-cap · listed on Nasdaq · headquartered in Minnesota.
2
The Numbers
Annual revenue in the range of roughly $100 million, with a business model built almost entirely around a single specialty molecule and the sterile manufacturing around it.
3
The History
The company has roots going back decades in fermentation and bioprocessing, eventually sharpening its focus to become a pure-play contract development and manufacturing operation.
4
The Secret
Its secret weapon is hyaluronic acid — a gooey biopolymer used in everything from eye surgery to injectable orthopedics — and it's one of the few U.S. producers that can make it at pharmaceutical grade.
5
The Lore
It spun off its food ingredient business to double down on biopharma CDMO services, betting that being the quiet supplier behind the syringe is more valuable than being the brand on the label.
6
The Giveaway
If your knee injection or cataract surgery used pharmaceutical-grade hyaluronic acid made in Chaska, Minnesota, this little Nasdaq CDMO probably filled that vial.

▶ Think you know your stocks? Play the Daily Ticker

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+0.5% YoY

$128.9MFY 2025

FY22 $185.8MFY23 $103.3MFY24 $128.3MFY25 $128.9M

Net Income

-422.6% YoY

$-38.7MFY 2025

FY22 $-116.7MFY23 $-99.6MFY24 $12.0MFY25 $-38.7M

Operating Income

-95.0% YoY

$-17.2MFY 2025

FY22 $-11.8MFY23 $-21.8MFY24 $-8.8MFY25 $-17.2M

EPS (Diluted)

-484.8% YoY

$-1.27FY 2025

FY22 $-3.97FY23 $-3.32FY24 $0.33FY25 $-1.27

Total Assets

-5.8% YoY

$239.3MFY 2025

FY22 $277.8MFY23 $253.5MFY24 $254.0MFY25 $239.3M

Total Debt

+6.6% YoY

$133.9MFY 2025

FY22 $196.4MFY23 $85.4MFY24 $125.6MFY25 $133.9M

Op. Cash Flow

-180.2% YoY

$-206.0KFY 2025

FY22 $-24.4MFY23 $-17.4MFY24 $257.0KFY25 $-206.0K

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2019
Revenue	$128.9M +0.5%	$128.3M +24.2%	$103.3M -44.4%	$185.8M +84.2%	$100.9M -81.9%	$557.6M
Net Income	$-38.7M -422.6%	$12.0M +112.0%	$-99.6M +14.7%	$-116.7M -257.3%	$-32.7M -8047.7%	$411.0K
Operating Income	$-17.2M -95.0%	$-8.8M +59.4%	$-21.8M -84.9%	$-11.8M -8699.3%	$-134.0K -102.4%	$5.5M
EPS (Diluted)	$-1.27 -484.8%	$0.33 +109.9%	$-3.32 +16.4%	$-3.97 -260.9%	$-1.10 -11100.0%	$0.01
Total Assets	$239.3M -5.8%	$254.0M +0.2%	$253.5M -8.7%	$277.8M -44.8%	$502.9M -3.1%	$519.1M
Total Debt	$133.9M +6.6%	$125.6M +47.1%	$85.4M -56.5%	$196.4M +19.1%	$164.9M +54.4%	$106.8M
Operating Cash Flow	$-206.0K -180.2%	$257.0K +101.5%	$-17.4M +28.5%	$-24.4M -248.1%	$16.5M +2.8%	$16.0M

AI Insight: LFCR Financial Trends

Revenue declined 34% from $35M in Q1 2025 to $23M in Q1 2026 while debt increased to $150M and equity turned deeply negative.

• Revenue dropped from $35M in Q1 2025 to $23M in Q1 2026, representing a 34% decline.

• Total debt increased consistently from $94M in Q4 2023 to $150M in Q1 2026.

• Equity deteriorated from $2M in Q1 2025 to negative $28M in Q1 2026.

• Operating income remained negative in most quarters, including $-5M loss in Q1 2026.

⚠ Missing revenue data for Q4 2025 despite positive operating metrics raises data quality concerns.

⚠ Company's negative equity position of $28M signals potential financial distress requiring monitoring.

AI Insight: LFCR Ratio Trends

Lifecore shows extreme volatility with operating margins swinging from +5.7% to -46.9% across quarters, while recent ROIC improved to 67.7% in Q4 2025 before declining again.

• Operating margin deteriorated from 5.7% in Q2 2024 to -20.1% in Q1 2026, showing persistent operational challenges.

• ROIC surged dramatically to 67.7% in Q4 2025 from negative levels throughout 2024-early 2025.

• Net profit margin remained deeply negative at -64.6% in the most recent quarter.

⚠ ROIC declined sharply from 67.7% in Q4 2025 to -15.4% in Q1 2026, questioning sustainability of recent improvement.

⚠ Extreme quarterly volatility in all profitability metrics suggests underlying operational instability or significant one-time items.

Get alerted when LFCR's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for LIFECORE BIOMEDICAL, INC. \DE\ including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of LFCR

22NW, LP
$18.9M1,254 sh
WYNNEFIELD CAPITAL INC
$17.5M4,703,216 sh
Legion Partners Asset Management, LLC
$16.6M4,461,823 sh
Greenhaven Road Investment Management, L.P.
$13.2M3,537,573 sh
325 CAPITAL LLC
$8.0M2,162,466 sh
BlackRock, Inc.
$7.0M1,877,305 sh
VANGUARD CAPITAL MANAGEMENT LLC
$4.8M1,290,136 sh
GRIZZLYROCK CAPITAL, LLC
$3.1M827,488 sh
GEODE CAPITAL MANAGEMENT, LLC
$3.0M815,107 sh
MORGAN STANLEY
$2.8M764,734 sh

Fund	Value	Shares
22NW, LP	$18.9M	1,254
WYNNEFIELD CAPITAL INC	$17.5M	4,703,216
Legion Partners Asset Management, LLC	$16.6M	4,461,823
Greenhaven Road Investment Management, L.P.	$13.2M	3,537,573
325 CAPITAL LLC	$8.0M	2,162,466
BlackRock, Inc.	$7.0M	1,877,305
VANGUARD CAPITAL MANAGEMENT LLC	$4.8M	1,290,136
GRIZZLYROCK CAPITAL, LLC	$3.1M	827,488
GEODE CAPITAL MANAGEMENT, LLC	$3.0M	815,107
MORGAN STANLEY	$2.8M	764,734

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put LFCR on your watchlist

Track score changes the day LIFECORE BIOMEDICAL, INC. \DE\ files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is LFCR a good stock to buy?

13F Pro's AI-powered analysis of LIFECORE BIOMEDICAL, INC. \DE\ (LFCR) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for LFCR are available on the LFCR stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own LFCR?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling LFCR. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of LIFECORE BIOMEDICAL, INC. \DE\'s investment landscape.